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Abstract
Background: Multiple sclerosis (MS) is a rare chronically debilitating disease. There are few reports on the burden
of disease of MS and prevalence in China. The authors intended to estimate disease burden and prevalence of MS
in Shandong Province using available epidemiologic data.
Methods: Prevalence was calculated using DISMOD II software based on incidence extrapolated from hospitalization
data, case fatality and remission rate from literature as input indexes. Disability-adjusted life year (DALY) was computed
with epidemiologic indexes estimated by DISMOD II program.
Results: The prevalence of MS was estimated to be 3.7(95 % CI: 1.65–5.8) and 6.7(95 % CI: 2.7–9.56) cases per 100,000
people for males and for females, respectively. The mean age at onset of MS was 36.0(43.0 ± 30.0 years in males and
33.7(43.4 ± 29.7) years in females. Duration of the disease was estimated to be 34.0 (31.6 ± 21.0) years for males and 39.
5(34.9 ± 21.8) years for females. The disease burden in disability-adjusted life years was 3316, comprised of 903 (27.2 %)
years of life lost (YLL) and 2413 (72.8 %) years lived with disability (YLD).
Conclusions: Our study highlighted that population in Shandong Province had a high prevalence of MS and
the patients had a heavy disease burden. It also revealed that the results obtained in this paper would be
useful to provide a reference for establishing specific healthcare policies for this rare disease in Shandong
Province.
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Background
Multiple sclerosis(MS) is a rare disease, characterized by
chronic course with intermittent relapses, usually ending
up with a severe debilitation [1]. Therefore, once diag-
nosed, patients with MS are forced to live with it for the
rest of their lives, leading to significant health, social,
and economic problems [2, 3].
According to previous studies, the prevalence of MS
has a wide variation. The estimated prevalence of MS is
203.4/100,000 in the United Kingdom and 94.7/100,000
in France, respectively [4, 5]. In the United States, the
prevalence of MS has been presumed to be approximately
100/100,000 [5]. The prevalence of MS is estimated to be
3.9 per 100,000 in Japan and 3.5 per 100,000 in Korea
[6, 7]. According to WHO, there are more than 2.5
million MS patients worldwide, accounting for 6.29 % of
the total neurologic diseases and disease burden of MS
accounts for 0.1 % of total disease burden of neurologic
diseases. It has been estimated that MS generates 2.9
person-years per 100,000 in Korea [8, 9].
Even though MS is also an intractable and chronically
debilitating rare disease in China, yet, until now, to the
best of our knowledge, no studies on the prevalence and
disease burden of MS are available. In addition, data from
other countries may not reflect the country-specific situa-
tions. The lack of these important epidemiological
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data has greatly limited the government to develop a
health policy for MS. Therefore, estimation of epide-
miologic indexes of MS in China is necessary. In this
study, the DISMODII was employed to estimate the
prevalence and disease burden of MS in Shandong
Province, China.
DISMODII is structured by two basic inputs: the con-
struction of population divided by gender and age, and
the entire mortality rate for each demographic group.
The model assumes a causal relationship between a set
of indicators relevant by age and gender: incidence,
prevalence, remission, mortality, duration, case fatality,
and the relative risk on total mortality [10, 11]. If three
of these disease variables (by age groups and gender) are
defined, DISMODII uses a set of mathematical equations
to derive an internally consistent set of epidemiological
parameters including the prediction of the other disease
parameters. In this study, incidence, case fatality and re-
mission rate were used as the three inputs.
Methods
Estimation of MS incidence in Shandong Province
Currently, China has no MS disease registration system.
In this study, we used the hospitalized patients of MS in
2013 to estimate the incidence of MS in Shandong
Province. The study was approved by the Shandong
Academy of Medical Sciences’ ethics committees. All
data used in this study were accessed in accordance with
ethical requirements and did not violate the privacy right
of individuals. The hospitalization data were obtained
from university-affiliated hospitals, and hospitals at pro-
vincial or municipal level from 17 cities in Shandong
Province in a national pilot project of rare diseases initi-
ated in China. The system contains registration files of
hospitalized patients, which include comprehensive
records of demographic data, dates of clinical visits,
diagnostic codes, details of prescriptions, and examina-
tions. Based on International Classification of Diseases
Ten Revision (ICD-10) code, we collected the patients
diagnosed with MS from the system and excluded those
patients with uncertainty or repeated registrations. The
incidence of MS was calculated using the number of
incident cases as the numerator and the Shandong
population in 2013 as the denominator.
Case fatality rate
Since case fatality rate is currently unavailable in China,
the relevant data of case fatality rate were obtained from
published research from Korea [9]. Data from Korea
were used as the reference were based on the following
considerations: on the one hand, Korea is the neighbor-
ing country with the closest racial comparisons to China
in Asia; on the other hand previous studies have demon-
strated that there is no significant correlation between
survival rate and latitude of regions among Asian races
and that the pathogenesis characteristics such as dis-
ease’s progress and age are of little difference.
Other data sources
Remission rate refers to a fraction of individuals with a
disease recovering to a normal state. Since MS is as-
sumed to be an irreversible disease, the remission rate is
deemed to be equal to zero [12]. The age- and gender-
specific population of Shandong Province was obtained
from the Statistics Office. Data on overall mortality were
drawn from Chinese Center for Disease Control and
Prevention.
Data analysis using DISMOD II software
To estimate prevalence and other epidemiologic data, all
data were broken down by age and gender. Incidence,
the case fatality and the remission rate, along with gen-
eral mortality and population were entered into DISMO-
DII. The equation calculated numerically using the finite
difference, an iterative approximation method. For esti-
mation purposes, the estimators were assumed to follow
a Poisson distribution.
Burden of disease
To estimate the disease burden, we adopted the ap-
proach used in the Global Burden of Disease study,
which has been used to estimate rare disease burden in
China [13]. According to this approach, DALY was the
sum of years of life lost (YLL) and years lived with dis-
ability (YLD). To calculate the YLD, number of incident
cases, disease duration, disability weight and age at onset
were entered into formula. The number of fatal cases
and the remaining life expectancy were added to the








Ni  Ii  Ti  D
Where Ei is the average expected years remaining, Di
the number of deaths, Ni the population susceptible to
MS at each age, Ii MS incidence by age group and sex, T
disease duration for each age group, and D is disability
weight.
In this study, the Coale and Demeny West Level 26
Life Table was adopted to calculate the remaining life ex-
pectancy [14]. Regarding to disability weight, no data
have been published in China. Therefore, a disability
weight value of 0.690 was adopted in this study. This
value was used for analysis of burden of disease of MS
patients in Korea [9]. The age-weighting and discounting
factors used in the GBD study were applied to calculate
DALY. In summary, DALY was calculated with a
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discount rate of 3 %, an age-weighting modulation factor
of k = 1 D, and a disability weight of 0.69.
Statistical analysis
All statistical analyses are carried out using SPSS 20.0
statistical software. The results are expressed as 95 %
confidence intervals (95 % CI) for prevalence. Mean ±
SD for are used to express continuous variables.
Results
Based on the hospitalization data, a set of patients diag-
nosed with MS for the first time in 2013 were obtained,
which were used to estimate the incidence of MS. As
seen in Table 1, this study demonstrated an increasing
incidence of MS with the increase in ages, peaking at
ages15–29 years and 30–44 years for female and male
patients, respectively. Generally, female patients had an
earlier onset and higher incidence than male patients.
In this research, the prevalence of MS was estimated
to be 3.7(95 % CI: 1.65–5.8) cases per 100,000 people for
males and 6.7(95 % CI: 2.7–9.56) cases per 100,000
people for females (Table 2). Furthermore, the preva-
lence tended to increase in both men and women with
the increase in ages, reaching a peak at age 45–59 years
for both sexes. The mean disease duration of MS was
34.0 and 39.5 years in males and females, respectively. It
was also estimated that female patients had an average
onset age of 33.7 years, which was slightly earlier than
the male patients (36 years) (Table 2).
The DALY rate of MS in the Shandong population
was 3.46 person-years per 100,000. The DALY rate of
women (4.46DALYs/100,000) was higher than that in
men (2.47DALYs/100,000). Moreover, DALYs in males
and females were both the highest in the age of 30–44
years (Table 3). In addition, as shown in Table 3, YLL
was 308 for males and 595 for females, whereas YLD
was 891 for males and 1515 for females, with a total of
3316. As seen in Fig. 1, it could be seen that different
groups of age and gender contributed significantly differ-
ently to DALY. With the increase in ages, the percentage
of DALY increased due to mortality (YLL). Nevertheless,
for patients aged59 years or younger, the most important
factor to DALY was morbidity.
Discussion
Although rare disease study is becoming more and more
interesting, the exploration of rare diseases epidemiology
is still novel in the field [15]. The obtaining of rare dis-
ease epidemiological data mainly depends on the disease
registration system or extrapolation from other data
resources. Currently, there is no specific registration sys-
tem for rare diseases in China, and the important epi-
demiological data, especially the prevalence and disease
burden of most rare diseases, are lacking. It has been
generally acknowledged that such situation represents a
major challenge for China to develop its medical policies
on rare diseases [16, 17].
The study uses an extrapolation approach based on
DISMOD II program to estimate disease burden and
prevalence of MS in Shandong Province, China. This
strategy has been applied to scleroderma and schizo-
phrenia in the previous studies [18, 19]. Representative
epidemiological indexes were input into the DISMOD
model, and it was found that both inputs and outputs
had almost the same distribution, indicating a sufficient
validity and reliability of this strategy. In this study, a
duration of disease of 34.0 and 39.5 years for males and
females, respectively, which was very well in line with
that reported in other countries. For example, the dur-
ation of disease is 32.5–49.2 years in Canadianand36 for
men and 43 years for women in Norway [20–22], sup-
porting the validity of this study.
Table 1 Input variables in DISMOD II modeling for multiple sclerosis in Shandong Province
Age Input
Incidence a(100000) Case fatality (100000) Total population b
Male Female Male Female Male Female
0–4 0.07 0.07 0.012 0.007 2937849 2396888
5–14 0.06 0.09 0.012 0.007 5210843 4528629
15–29 0.12 0.36 62.7 47.6 11096477 10788151
30–44 0.23 0.28 607.6 509.5 11963422 11776850
45–59 0.11 0.13 1312.2 1364.0 10505956 10457193
60–69 0.05 0.05 2046.6 1864.5 3911022 3936225
70–79 0.14 0.08 2257.7 1574.8 2119215 2342429
80+ 0.0007 0.0007 1979.9 2062.5 702160 1119410
Total 0.098 0.13 NA NA 48446944 47345775
aIncidence was estimated using the number of hospitalized patients as the numerator and the Shandong Province population in 2013 as the denominator
bShandong population in 2013
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A prevalence of MS of 5.2/100,000 people was ob-
tained in Shandong in this study, which was higher than
that in Japan (3.9/100,000) and Korea (3.5/100,000), and
much lower than that in European countries (203.4/
100,000 in United Kingdom, 94.7/100,000 in France) and
the United States (100/100,000). It should be noted that
the incidence of MS was calculated in this study with
the hospitalization data against Shandong population, it
is inevitable that those outpatients diagnosed with MS
would not be included and some other patients with MS
might be hospitalized in other hospitals that were not
covered in this study. Therefore, the parameters of MS
we used in this study might represent the low limit and
the prevalence of MS obtained should be regarded as
the lowest prevalence in Shandong Province.
Incidence and prevalence are often used as one meas-
ure index of disease frequency since their calculation
only concerns the number of cases and the basic popula-
tion. However, DALYs consider not only survival time
but also life quality caused by a certain disease and their
calculation requires age and sex dependent incidence,
case fatality, severity of disease and life expectancy.
Therefore, DALY is a more comprehensive health indi-
cator to demonstrate the threat of some disease to the
whole population. In this study, the major contributing
factor to DALY was YLD, indicating that most of the
burden of disease was from the loss due to disability
from the disease. This result demonstrated that MS
could cause high disease burden since it occurs mainly
at childbearing age. The DALY rate was estimated to
be3.46 person-years per 100,000 in Shandong, which
was slightly higher than that reported in Korea(2.9 per-
son- years per 100,000) [9], therefore, more attention
should be paid to MS in Shandong Province with the
limited health resources.
In our study, we provide clear evidence that there is a
large population of MS patients with a high disease bur-
den in Shandong Province. Despite the lack of specific
treatment to cure MS, some orphan drugs have been vali-
dated to bring about a notable improvement in quality of
life. However, most of the orphan drugs targeting MS are
still unavailable in China. We believe that these
Table 2 Modeled incidence (per 100000 population), prevalence (per 100000 population), age on set, death cases and disease
duration by age groups and gender
Output
Age Incidence Prevalence Duration (yr) Age of onset (yr) Death cases
Male Female Male Female Male Female Male Female Male Female
0–4 0.07 0.07 0.18 0.18 63.7 68.3 2.5 2.5 0 0
5–14 0.06 0.09 0.67 0.8 56.9 61.0 9.5 10.0 0 0
15–29 0.12 0.37 1.6 3.1 42.8 46.3 24.1 25.0 0 0
30–44 0.22 0.27 4.7 8.9 32.1 35.7 36.7 37.2 4 6
45–59 0.12 0.14 6.2 10.4 22.7 26.1 50.2 50.4 8 15
60–69 0.05 0.05 5.8 9.4 14.4 18.0 65.1 65.0 5 7
70–79 0.13 0.08 5.4 8.5 10.5 13.4 75.7 75.0 3 3
80+ 0.02 0.02 5.3 7.8 9.8 10.6 82.5 82.5 1 1
Total 0.12 0.2 3.7 6.7 34.0 39.5 36.0 33.7 21 32
Table 3 Years of life lost (YLL), years lived with disability (YLD) and disability-adjusted life year (DALY) due to multiple sclerosis in
Shandong Province
Age Male Female Total
YLL YLD DALY YLL YLD DALY YLL YLD DALY
0–4 0 40 40 0 34 34 0 74 74
5–14 0 57 57 0 80 80 0 137 137
15–29 0 236 236 0 697 697 0 933 933
30–44 70 374 444 147 486 633 217 860 1077
45–59 151 149 300 301 185 486 452 334 786
60–69 69 16 85 108 19 127 177 35 212
70–79 18 19 37 32 14 36 50 33 83
80+ 0 0 0 7 0 7 0 7 7
Total 308 891 1199 595 1515 2110 903 2413 3316
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epidemiologic data obtained in this study will contribute
to provide a reference for the development of specific
health policies on MS in the future. In addition, these in-
dexes can serve as the basis of epidemiological data for in-
dividual disease that can fill in the gap of research on rare
diseases whose research has been lagging in China. This
evidence-based study on MS will also be useful for pro-
moting industry to research and develop innovative or-
phan drugs for the treatment of this devastating rare
disease.
Although our results are promising, the limitations of
the present study should be addressed. The first is that
the effects of some factors, such as social and economic
status, health services and environmental hygiene, were
not quantified precisely. With this regard, the WHO
standards, the widely accepted world standards, were
adopted in this study. However, there are some discrep-
ancies between the standards and the actual domestic
environment. The second is that the data used to calcu-
late incidence are insufficient. However, the reality in
China is that rare disease data are divided into different
age groups or come with restrictive conditions, making
it difficult to use them. In addition, previous study has
demonstrated that 92.5 % of rare diseases are diagnosed
in university hospitals, provincial hospitals, and munici-
pal hospitals [16]. And China has taken a series of
effective measures and attempts to improve the diag-
nosis of rare diseases [23]. Therefore, the incidence
obtained in this study is appropriate for use. In the
future, we would collect more MS information to
complement this study. We believe when these data
become available, we can estimate epidemiological
parameters more precisely.
Conclusion
In this study, using a DISMODII model, we estimated
prevalence and disease burden of MS in Shandong
Province. Our data indicate that there are a large number
of MS patients with high disease burden in Shandong
Province, and that the current healthcare policies need to
be emphasized on this severe rare disease. The result of this
paper also contributes significantly to the international
readers because there are no reports available for them on
the prevalence and disease burden of MS in China.
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